Thought Leader Liaison Director - Hematology

Thought Leader Liaison Director - Hematology

Employer: Sumitomo Pharma. Sumitomo Pharma Co., Ltd., is a global pharmaceutical company based in Japan with operations in the U.S. (Sumitomo Pharma America, Inc.), focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With several marketed products and a diverse pipeline of early- to late-stage investigational assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn. We are currently seeking a dynamic, motivated, and experienced individual for the position of Thought Leader Liaison Director – Hematology (Enzomenib). This field-based role will focus on shaping the external thought leader ecosystem and pre-launch readiness for enzomenib, while also supporting the eventual transition to an in-market commercial role. The TLL will engage hematology thought leaders across academic centers and leading community institutions, generate insights to inform launch planning and strategy, and ensure continuity of engagement and impact through commercialization. Essential Functions Required for Job: - Develop and execute a pre-launch thought leader engagement plan for enzomenib, including identification, profiling, and prioritization of key hematology/oncology experts and emerging voices. - Map the thought leader landscape, influence pathways, and treatment ecosystem to inform launch targeting, segmentation, and engagement strategy - Build and strengthen relationships with thought leaders in acute leukemia and related hematologic malignancies, aligning engagement with development and launch milestones - Capture and synthesize external insights on unmet need, treatment patterns, diagnostic considerations, and adoption barriers, translating findings into actionable launch strategy implications - Partner cross-functionally to shape advisory board strategy and